Structure of Pi3K gamma with a potent inhibitor: GSK2126458

Experimental Data Snapshot

  • Resolution: 2.70 Å
  • R-Value Free: 0.261 
  • R-Value Work: 0.198 
  • R-Value Observed: 0.201 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.4 of the entry. See complete history


Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.

Knight, S.D.Adams, N.D.Burgess, J.L.Chaudhari, A.M.Darcy, M.G.Donatelli, C.A.Luengo, J.I.Newlander, K.A.Parrish, C.A.Ridgers, L.H.Sarpong, M.A.Schmidt, S.J.Van Aller, G.S.Carson, J.D.Diamond, M.A.Elkins, P.A.Gardiner, C.M.Garver, E.Gilbert, S.A.Gontarek, R.R.Jackson, J.R.Kershner, K.L.Luo, L.Raha, K.Sherk, C.S.Sung, C.M.Sutton, D.Tummino, P.J.Wegrzyn, R.J.Auger, K.R.Dhanak, D.

(2010) ACS Med Chem Lett 1: 39-43

  • DOI: https://doi.org/10.1021/ml900028r
  • Primary Citation of Related Structures:  
    3L08, 3L54

  • PubMed Abstract: 

    Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

  • Organizational Affiliation

    GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform966Homo sapiensMutation(s): 0 
Gene Names: PIK3CG
UniProt & NIH Common Fund Data Resources
Find proteins for P48736 (Homo sapiens)
Explore P48736 
Go to UniProtKB:  P48736
PHAROS:  P48736
GTEx:  ENSG00000105851 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP48736
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on ZIG

Download Ideal Coordinates CCD File 
D [auth A]2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide
C25 H17 F2 N5 O3 S
Query on SO4

Download Ideal Coordinates CCD File 
B [auth A],
C [auth A]
O4 S
Binding Affinity Annotations 
IDSourceBinding Affinity
ZIG PDBBind:  3L08 Ki: 0.06 (nM) from 1 assay(s)
BindingDB:  3L08 IC50: min: 0.44, max: 1.2 (nM) from 4 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.70 Å
  • R-Value Free: 0.261 
  • R-Value Work: 0.198 
  • R-Value Observed: 0.201 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 145.617α = 90
b = 68.41β = 94.72
c = 107.47γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
PHENIXmodel building
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-06-23
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2018-04-18
    Changes: Data collection, Database references
  • Version 1.3: 2024-02-21
    Changes: Data collection, Database references, Derived calculations
  • Version 1.4: 2024-04-03
    Changes: Refinement description